Epizyme to Participate in Upcoming September Conferences

CAMBRIDGE, Mass.--()--Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following September investor conferences:

  • Citi 14th Annual Biotech Conference’s “Focusing the Laser on Precision Oncology - Part 2” Company Panel on Thursday, Sept. 5, 2019 at 9:30 a.m. ET in Boston; and,
  • Morgan Stanley 17th Annual Global Healthcare Conference (fireside chat) on Monday, Sept. 9, 2019 at 3:40 p.m. ET in New York City.

Live webcasts will be available in the investor section of the company's website at www.epizyme.com. The webcasts will be archived for 60 days following the presentations.

About Epizyme, Inc.
Epizyme, Inc. is a late-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, an oral, first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.

Contacts

Media:
Erin Graves, Epizyme, Inc.
media@epizyme.com
(617) 500-0615

Investors:
Chelcie Lister, THRUST Strategic Communications
chelcie@thrustsc.com
(910) 777-3049

Contacts

Media:
Erin Graves, Epizyme, Inc.
media@epizyme.com
(617) 500-0615

Investors:
Chelcie Lister, THRUST Strategic Communications
chelcie@thrustsc.com
(910) 777-3049